Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
11Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Ventyx Biosciences Inc (VTYX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
3Distinct source URLs
8High confidence
0.766Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Ventyx Biosciences Inc Suppliers
Ticker
Name
Confidence
Evidence
BAYSIDE
BAYSIDE
90%
Expense recognized by the Company under the related party Support Services Agreement with Bayside was as follows (in thousands): Three months ended Nine months ended September 30, September 30, 2025 …
SANOFI
SANOFI
90%
In connection with the Securities Purchase Agreement, the Company granted Sanofi a right of first negotiation ("ROFN") for a license, grant or transfer, including by option or sale, or any rights to …
JEFFERIES
JEFFERIES
85%
In December 2022, the Company entered into an Open Market Sales Agreement SM ("Sales Agreement") with Jefferies, as sales agent, pursuant to which the Company may offer and sell in an at-the-market o…
Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of t…
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each share of the Company’s common stock, par v…
NLRP3 inhibitor. The Company evaluated the ROFN for performance obligations under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”) concluding that ther…
Reciprocal relationship from NBIX graph: Reciprocal relationship from VTYX graph: NLRP3 inhibitor. The Company evaluated the ROFN for performance obligations under Accounting Standards Codification (…
SNYNF
Sanofi
72%
ember 23, 2024, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Aventis Inc., a wholly-owned subsidiary of Sanofi, a global healthcare and pharmace…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VTYX graph: ember 23, 2024, the Company enter…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome,…
IN-CATALYST-PHARMS-INC
IN-CATALYST-PHARMS-INC
62%
itional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to mark…
KALIKA-BIOSCIENCES-INC
KALIKA-BIOSCIENCES-INC
62%
. Our pending and future patent applications may not result in patents being issued or issued patents may not afford sufficient protection of our product candidates or their intended uses against com…
ROCHE-AG
ROCHE-AG
62%
l approval or administrative actions; ▪ delays in our ability to commence a clinical trial; ▪ reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which…
VIMALAN-BIOSCIENCES-INC
VIMALAN-BIOSCIENCES-INC
62%
laws and regulations relating to privacy, data protection, or data security and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure y…
Ventyx Biosciences Inc Debt Obligations
Instrument
Description
Confidence
Evidence
VTYX-DEBT-13467
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
VTYX-DEBT
Debt stack $10.0M
90%
Market cache reports total debt of $10.0M.
Ventyx Biosciences Inc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Ventyx Biosciences Inc.
Ventyx Biosciences Inc Ownership
Holder
Name
Confidence
Evidence
VTYX-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 7 tracked holders.
